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Acute kidney injury (AKI) has been a global health epidemic problem with soaring incidence, increased long-term
risks for multiple comorbidities and mortality, as well as elevated medical costs. Despite the improvement of patient
outcomes following the advancements in preventive and therapeutic strategies, the mortality rates among critically
ill patients with AKI remain as high as 40–60 %. The distant organ injury, a direct consequence of deleterious
systemic effects, following AKI is an important explanation for this phenomenon. To date, most evidence of remote
organ injury in AKI is obtained from animal models. Whereas the observations in humans are from a limited
number of participants in a relatively short follow-up period, or just focusing on the cytokine levels rather than
clinical solid outcomes. The remote organ injury is caused with four underlying mechanisms: (1) “classical” pattern
of acute uremic state; (2) inflammatory nature of the injured kidneys; (3) modulating effect of AKI of the underlying
disease process; and (4) healthcare dilemma. While cytokines/chemokines, leukocyte extravasation, oxidative stress,
and certain channel dysregulation are the pathways involving in the remote organ damage. In the current review,
we summarized the data from experimental studies to clinical outcome studies in the field of organ crosstalk
following AKI. Further, the long-term consequences of distant organ-system, including liver, heart, brain, lung, gut,
bone, immune system, and malignancy following AKI with temporary dialysis were reviewed and discussed.
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Acute kidney injury (AKI) is a common clinical problem
affecting up to 1 % of the general population and 8-15 %
of hospitalized patients [1–3], and the incidence is in-
creasing worldwide [4, 5]. Among the critically ill pa-
tients, about 50 % develop AKI and 4–15 % have severe
AKI needing renal replacement therapy (RRT) support
[6, 7]. Besides, AKI was found to be an independent pre-
dictor for end-stage renal disease (ESRD) in a large co-
hort study enrolling 233,803 elderly patients, and the
impact of AKI on developing ESRD was even higher
than that of previous chronic kidney disease (CKD) (haz-
ard ratio (HR) of AKI alone and CKD alone, comparing* Correspondence: q91421028@ntu.edu.tw
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spectively) [8]. On the other hand, AKI has varied renal
recovery rates ranging from 30 % to 70 % in diverse pa-
tient types [9].
AKI carries widely-ranged risks of morbidity and mor-
tality in a stepwise manner which increase concurrently
with increasing severity and duration of AKI, and even
mild temporary AKI is associated with increased mor-
bidity and mortality [8–11]. In addition, the different
AKI recovery status might also attribute to mortality
and morbidity [9, 10]. Thus AKI has been a global health
epidemic problem with soaring incidence, increasing
long-term risks for multiple comorbidities and mortality,
along with growing healthcare costs [9, 11–13]. Owing
to the advancements in preventive and therapeutic strat-
egies, the AKI-associated mortality rates exhibited a sig-
nificantly declining trend over the decades in both
general hospitalized patients [14, 15] and critically ills distributed under the terms of the Creative Commons Attribution 4.0
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ically ill patients with AKI remain as high as 40–
60 % [7, 16]. Even with survival from the catastrophic
AKI events, they sequels of multi-organ damage are dis-
concerting. One of the possible explanations for this
phenomenon is that the RRT, a currently most effective
therapy for severe AKI, itself may also carry adverse side
effects [17]. Another and perhaps a more important ex-
planation is the distant organ injury, a direct consequence
of deleterious systemic effects, following AKI [18, 19]. An
increasing body of evidence supports that the extra-renal
complications are at least partially responsible for the bur-
den of mortality from AKI [20, 21]. Actually, AKI is often
resulted from distant organ injury or systemic illness such
as sepsis, and AKI can in turn cause extra-renal organ
dysfunction [16, 18]. The term “organ crosstalk” is used to
describe “the effects of one dysfunctional organ on the
function of another” or “the reciprocal trigger of organ
dysfunction of two different organs” [18, 19].
Although the concept of organ crosstalk in AKI is be-
ing gradually established, most of the evidence is ob-
tained from animal models [22–24]. The observations in
humans are from a limited number of participants in a
relatively short follow-up period, [25] or just focusing on
the cytokine levels rather than clinical solid outcomes
[26]. As such, little is clearly understood on distant
organ injury following AKI [18]. The aim of this review
is to update the knowledge, from basic aspect to long-
term clinical effect, regarding the remote organs conse-
quences following AKI. The organ crosstalk goes from
other organs to kidney resulting in AKI will not be cov-
ered in this review.
Distant organ consequences following AKI (Fig. 1)
AKI is gradually considered a pan-metabolic, pan-
endocrine and pan-organ problem which exerts negative
consequences on many organ systems of the body
[27–29]. Briefly speaking, the systemic effects are the
reflection of a broad common pathology which ultim-
ately causes an ‘augmented’ inflammation and impair-
ment of immunocompetence during AKI [29, 30]. These
multifaceted systemic effects could be categorized into
four underlying mechanisms: (1) “Classical” pattern of
acute uremic state which affects all metabolic and endo-
crine pathways, causes disruption of electrolyte and vol-
ume homeostasis, and further proximate factors have a
profound impact on immuno-competence [31–33]. (2) In-
flammatory nature of the injured kidneys. Animal stud-
ies disclosed that injured kidneys may cause obviously
higher inflammatory chemokines expression and renal fi-
brosis [34] as well as profound iron-mediated oxidative
stress by disturbing systemic iron homeostasis [35], while
supplement with hepcidin may increase the expression of
renal H-ferritine and exhibit renal-protective effect [35].The association between AKI and infection susceptibility
is plausible given that acute kidney insults are known to
induce changes in gene regulation, oxidative stress, in-
flammation, leukocyte trafficking, and apoptosis and to in-
cite systemic and distal organ injury. The inflammatory
process might eventually transform into systemic inflam-
matory reaction mediating distant organ injury [24, 36].
(3) Modulating effect of AKI of the underlying disease
process. A great modulating effect on the underlying dis-
ease process of other organ-systems would be induced by
the disturbed cytokine/chemokine homeostasis in AKI,
which may be attributable to the decreased renal clearance
and/or increased production of these cytokine/chemokine
[34, 35, 37–39]. (4) Healthcare dilemman RRT support is
generally considered as necessary for AKI patients with
profound biochemical disarrangement or fluid overload
[40]. However, RRT itself is proven to carry significant
risks for adverse patient outcome owing to the hemo-
dynamic instability and nutrients loss during RRT, as well
as reactive oxygen species and inflammatory reaction sec-
ondary to the bio-incompatibility of artificial kidney, and
the use of unfractionated heparin [17, 30, 41, 42]. The ad-
equate serum level of antibiotics and anticoagulant are
also difficult to achieve and maintain in AKI patients with
RRT [17], which may disturb infection control or cause
complications. Besides, the use of mechanical ventila-
tion and hemodialysis catheters also raise the risk of
complications.
Based on the aforementioned mechanisms, several
complex pathways are involved in the crosstalk of organs
during AKI, causing injury in distant organ-systems in-
cluding neuromuscular, cardiovascular, pulmonary, gas-
trointestinal, hepatobiliary, immunologic, hematologic,
and metabolic systems [18, 19, 21, 30, 39].
Long-term remote organ consequences following AKI
with temporary dialysis
This review focused on the long-term pivotal effects of
de novo RRT-requiring AKI on extra-renal organ sys-
tems. To avoid the confounding detrimental effects of
chronic RRT, which has been proven to result in worse
patient outcomes, the following review only covered
studies in which the enrolled subjects were limited to
those recovered from the most severe form of AKI, i.e.
those with transient RRT-requiring AKI (Table 1).
Kidney-heart crosstalk
Most patients with acute decompensated heart failure
have underlying renal insufficiency, which, alone or
along with acute renal insults, expose the patients to ad-
verse clinical outcomes [43–45]. The effects of cardiac
failure on kidney injury may be through hemodynamic-,
humoral- and immune-mediated pathways [46–49]. Re-
versely, AKI may also result in acute cardiac disorder via
AKI
1. “Classical” pattern of acute uremic state.
2. Inflammatory nature of the injured kidney.
3. Modulating effect of AKI of the underlying disease process.
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Four underlying mechanisms:
Fig. 1 Proposed mechanism of distant organ consequences following AKI [17, 18, 21, 24, 30–42]. Abbreviations: AKI, acute kidney injury; RRT, renal
replacement therapy
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ary to AKI-induced salt and water retention; (2) myocar-
dial damage due to neutrophil trafficking, myocyte
apoptosis, endothelial dysfunction, as well as elevated
level of inflammatory cytokines (interleukin (IL)-1, IL-6,Table 1 Long-term remote organ consequence following AKI unde
Outcomes Hazard ratio (95 % Confidence interval)
No-AKI Recovery-AKI N
Coronary event Reference 1.67 (1.36–2.04)a –
Upper gastrointestinal bleeding Reference 1.30 (1.14–1.48)a ES
2.
Incident Stroke Reference 1.25 (1.10–1.65)a –
Severe sepsis Reference 1.58 (1.15–2.16)a ES
1.
Active tuberculosis Reference 3.84 (2.07–7.10)a 6.
Malignancy 0.66 (0.45–0.98)c Reference 1.
Bone fracture Reference 6.59 (2.45–17.73)a –
Data are represented as Hazard Ratio (95 % Confidence Interval)
All the studies defined renal recovery by independence from RRT are population-ba
defined by RRT initiation, while recovery defined by withdraw from RRT
Abbrevations: AKI acute kidney injury, ESRD end-stage renal disease, f/u follow up
aStatistical significancy comparing with no-AKI group
bMatched patients
cStatistical significancy comparing with recovery-AKI group
dStatistical significancy comparing with non-recoveryAKI groupand tumor necrosis factor (TNF)-α) resulting from in-
creased production and impaired clearance [21, 50–52].
To identify the association of AKI with long-term
cardiovascular risk, Wu et al. [12] compared 4,869 pa-
tients who recovered from de novo RRT-requiring AKIrgoing RRT
References and details
on-recovery AKI
Wu et al. [12]; n = 4,869x2b; mean f/u: 3.31 yrs
RD after AKI recovery
31 (1.92–2.79)a
Wu et al. [87]; n–4,565x2b; median f/u: 2.33 yrs
Wu et al. [60]; n = 4,315x2b; median f/u: 3.36 yrs
RD after AKI recovery
99 (1.71–2.31)a
Lai et al. [103]; n = 2,983 + 11,932b; median
f/u: 3.96 yrs
39 (3.57–11.45)a Wu et al. [68]; n = 2,909 + 11,636b; mean f/u: 3.6 yrs
49 (1.02–2.03)c Chao et al. [100]; n = 623x3b; mean f/u: 3.7 yrs
Wang et al. [92]; n = 448 + 1,792b; mean f/u: 3.9 yrs.
sed study based on Taiwan National Health Insurance Research Database. AKI
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patients (no-AKI group). To make an unbiased estimate
of the confounders, propensity score method was used
to adjust baseline characteristics which might affect dia-
lysis withdrawal and subsequent patient outcomes. The
control group (no-AKI group) was matched with the ex-
posure group (recovery-AKI group) on the basis of age,
sex, same calendar year of index hospitalization, and co-
morbidities before and during index hospitalization. Fur-
thermore, the results were further validated by analysis
of a prospectively constructed database.
With a mean follow-up period of 3.31 years, the pa-
tients in “recovery-AKI group” had 1.7 times higher risk
of coronary events than “no-AKI group”, independent of
the effects of subsequent progression to CKD and ESRD.
In an adjusted comparison, “RRT-requiring AKI alone”
(3.3 times hazard) was associated with even higher long-
term coronary events than “diabetes alone” (2.8 times
hazard). Furthermore, adjusting for interim coronary
events attenuated the association between RRT-requiring
AKI and subsequent risk of death, supporting the hypoth-
esis that coronary events are in the causal pathway linking
AKI and mortality. The study substantiated the interaction
of cardiorenal syndrome type 3, which describes impaired
myocardial function by various interconnected pathways
in AKI [53]. The association between AKI and subsequent
risk for cardiac events were also identified in some other
studies [54, 55].
Kidney-brain crosstalk
AKI has neurological complications including dizziness,
attention deficits, tremor, seizure, altered mental status,
delirium, and even death [21]. Cellular and soluble in-
flammatory mediators as well as uremic toxins contrib-
ute to the neurological symptoms. Animal studies using
mice found that AKI may subsequently result in
increased vascular permeability, disruption in the blood-
brain barrier, increased cerebral proinflammatory cyto-
kines (IL-6, IL-1β, IL-12, keratinocyte-derived chemokine,
granulocyte-colony stimulating factor, and glial fibrillary
acidic protein), and increased neuronal pyknosis and
microgliosis (up-regulation of brain macrophages) [21, 23].
Microgliosis is a hallmark of cerebral inflammation and is
implicated in the pathology of neurodegenerative diseases
[56]. Alterations in calcium concentrations, water hand-
ling and neurotransmitter turnover may also play roles in
functional changes in the brain after AKI [21]. Addition-
ally, posterior reversible encephalopathy syndrome (PRES)
has been reported in AKI patients with [57] and without
hypertension [58]. Hypertension that exceeds the limits of
auto-regulation of the brain, immune response and endo-
thelial dysfunction may account for the development of
PRES [58]. Reversely, although about one-fourth of hospi-
talized patients with acute stroke develop AKI, the renalchanges secondary to neurological illness is less estab-
lished [21]. Increased inflammation is observed in renal al-
lografts from brain-dead donors [59].
A study determining the long-term effect of AKI on
de novo stroke was carried out with a median follow-up
period of 3.36 years [60]. The patients in “recovery-AKI
group” (n = 4,315) had 1.3 times elevated risk of develop-
ing incident ischemic and hemorrhagic stroke than those
in “no-AKI group” (n = 4,315) regardless of progression to
subsequent CKD. The risk factors for kidney injury lead-
ing to an AKI event may persist and eventually lead to fu-
ture stroke without a direct causal association with
preexisting CKD. AKI may thus amplify the long-term risk
of incident stroke and mortality, and the impact is similar
to diabetes.
Over the 3 years of follow-up, RRT-requiring AKI is
associated with an increased risk of dementia after crit-
ical illness [61]. Other independent risk factors include
infection, severe sepsis [61], and a prolonged duration of
delirium [62]. In this regard, interventions directed at re-
ducing delirium and preserving renal function may miti-
gate brain injury associated with critical illness.
Kidney-immune system crosstalk
The profound impact on immunocompetence is one of
the most important complications of AKI since kidney is
an important immunologic organ. AKI can cause short-
and long-term, either renal or systemic, immune-
modulation. First of all, both T cell population and
phenotype alteration within and outside the kidney were
observed in animal model after ischemic/reperfusion
kidney injury [63, 64], and these changes can last for
about three months. Moreover, either ischemia/reperfu-
sion injury itself or protein binding uremic toxin can
leads to epigenetic modifications resulting in distinct
genomic signatures [36, 65, 66]. In concordance to these
findings, our group had also observed an increase in
long-term risk of severe sepsis and tuberculosis after
RRT-requiring AKI. The adjusted risk of developing se-
vere sepsis prompting hospitalization was approximately
two-fold higher among AKI survivors compared to non-
AKI patients (incidence rate of 6.84 versus 2.32 per 100
person-years) [67]. Patients who recover from RRT-
requiring AKI also had significantly higher incidence of
TB than patients without AKI (HR, 3.84; p, 0.001) [68].
Taken together, studies from bench to bedside all
showed that AKI alters host immunocompetence even
after renal function recovery, and these alterations could
affect patient’s long-term outcome.
On the other hand, several studies have shown that
certain cytokine or chemokine gene polymorphism are
related to the occurrence or severity of AKI. In clinical
studies, TNF-α and IL-10 phenotype predict AKI and mor-
tality in hospitalized patients [69, 70], while transforming
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[71]. C-C chemokine receptor 5 knock-out mice showed
increased susceptibility to lipopolysaccharide‑induced
acute renal injury [72]. It is therefore reasonable to postu-
late that certain genetic backgrounds would affect the sus-
ceptibility to immune derangement, inflammation, sepsis
and AKI, whichever happens first.
Kidney-lung crosstalk
Respiratory consequences are the most clinically relevant
distant organ injury in AKI, and AKI is also commonly
seen in patients with pulmonary inflammation and mech-
anical ventilation [21, 30]. AKI alters peripheral vascular
responses by increasing oxidative stress, likely in the endo-
thelium [73]. As to renal cytokine production, comple-
ment activation, toll-like receptor-2, and toll-like receptor
4 signaling contribute to cytokine production after AKI
[74, 75]. Experimental studies demonstrated that AKI re-
sults in lung injury via following pathways: (1) lung edema,
which may be resulted from increased pulmonary vascular
permeability and dysregulated ion transport channels; (2)
increased cytokines and chemokines related to impaired
renal clearance and increased production; and (3) in-
creased leukocyte trafficking with mononuclear phagocyte
production. Besides, AKI may express modulatory effects
that vary with the severity of lung injury [21, 76].
Following AKI, serum IL-6 increases in the absence of
a counter anti-inflammatory response by spleen, and it
brings an exuberant proinflammatory response and me-
diates lung injury via Chemokine (C-X-C motif ) ligand 1
production in mice [77, 78]. In clinical studies, inflam-
matory cytokines, such as IL-6 and/or IL-8, are potential
mediators of the distant organ damage from AKI. Serum
IL-6 correlates with endothelial dysfunction in human
[79], while elevated levels of IL-6 are associated with
prolonged ventilator weaning times and increased mor-
tality in patients with AKI and acute lung injury [80].
A study evaluating the long-term risk and outcome of
active tuberculosis after AKI was conducted enrolling
2,909 RRT-requiring AKI patients (AKI-group) and
11,636 control individuals (no-AKI group) with a mean
follow-up period of 3.6 years [68]. The “AKI-group” had
7.7 times higher risk of active tuberculosis than general
population. Comparing with “no-AKI group”, the “recov-
ery-AKI group” had 3.8 times, and “non-recovery AKI
group” had 6.4 times elevated risk of getting tubercu-
losis. Besides, active tuberculosis was associated with 1.3
fold increased risk of long-term all-cause mortality after
RRT-requiring AKI. These results raise concerns that
the increasing global burden of AKI would also increase
the incidence of active tuberculosis. The increased long-
term risks for severe sepsis and tuberculosis might be
the results of impaired pulmonary and immunologic
function implicated by AKI.Kidney-gut crosstalk
Gut is a newly-found organ which would be remotely in-
jured during AKI. The inflammatory response and
hypervolemia related to AKI alter the permeability of
mesenteric vascular bed and promote the formation of
intestinal edema, which is a hallmark of intestinal failure
in sepsis [81]. Gut has been known as an amplifier of
systemic inflammatory response syndrome in the setting
of shock, gut hypoperfusion [82] and intestinal edema
[81] through the mechanisms including increased intes-
tinal permeability, disruption of mucosal integrity, liber-
ation of proinflammatory mediators, translocation of
intestinal microorganisms and resultant endotoxinemia.
The augmented systemic inflammatory reaction by gut
would in turn aggravate AKI, giving rise to a vicious
cycle.
Malnutrition and calorie deficit are associated with
poor renal outcome and mortality in AKI patients. The
condition is moreover complicated by changes in gut
mobility, insulin resistance, and hypercatabolic state due
to inflammatory mediators and neuroendocrine derange-
ment [83]. Despite the lack of large-scale randomized
controlled trials in the AKI population, early enteral nu-
trition should be used to preserve gut function and pos-
sibly to prevent stress ulcer hemorrhage [84, 85]. A
recent multicenter, randomized controlled trial showed
that early parenteral nutrition to supplement insufficient
enteral nutrition does not increase the incidence of AKI,
but prolongs the duration of renal replacement therapy
[86]. Nutritional requirements should be individualized
and frequently reassessed to avoid under- or overfeeding,
azotemia, hyperglycemia, hypertriglyceridemia, electro-
lyte and acid-base imbalance, and fluid overload [85].
After a median follow-up period of 2.33 years, Wu
et al. [87] disclosed that “recovery-AKI” was an inde-
pendent predictor of long-term upper gastrointestinal
bleeding, and that upper gastrointestinal bleeding was a
significant risk factor of long-term mortality. The re-
ported incidence of upper gastrointestinal hemorrhage
following transient RRT-requiring AKI was about one
hundred times greater than that of the general popula-
tion. Peptic ulcers accounted for two-thirds of upper
gastrointestinal bleeding episodes following AKI. Al-
though AKI incites inflammation, an “immunoparalysis”
state, similar to that ensuing from sepsis and critical
illness [88, 89], may follow and render the effects of
Helicobacter pylori more pernicious. The long-term inci-
dence of upper gastrointestinal bleeding in patients with
“recovery-AKI” (15–20 %) outnumbers the short-term
incidence in critically ill patients (1–6 %) [90], suggesting
the impact of AKI on the microvascular injury [91]
might last long, although a compelling mechanism re-
mains obscure. The high accumulation rates of nonste-
roidal anti-inflammatory drugs and anti-platelets use
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ity of gastrointestinal bleeding. Physicians should be
more prudent about the use of ulcerogenic agents in this
patient population.
Kidney-bone crosstalk
Wang et al. [92], by using a nationwide population-
based cohort study, evaluated the associations between
AKI and long-term risk on bone fractures. After a series
of selecting and matching process, a “recovery-AKI
group” containing 448 patients who developed transient
RRT-requiring AKI for less than 90 days and who didn’t
have diagnosis of bone fracture, and a “no-AKI group”
containing 1,792 propensity score-matched individuals
(with 1:4 ratio) without AKI or RRT were identified.
Comparing with the “no-AKI group”, those in “recovery-
AKI group” had 6.5 folds higher risk of developing bone
fracture in a mean follow-up period of 3.9 years. Even
after adjustment with other covariates, AKI is still inde-
pendently associated with higher risk of bone fracture
irrespective of subsequent development of ESRD. Long‐
term bone fractures may also negatively impact patient
mortality.
AKI is thought as a renowned predecessor of CKD
[93] because the pathological changes of renal osteody-
strophy occur earlier than previously expected CKD
stages [94], and dysregulated mineral hormones also
occur in AKI. It is plausible that earlier changes in vita-
min D metabolites and/or fibroblast growth factor
(FGF)-23 levels during AKI are responsible for the sub-
sequent bone structural abnormalities [92]. Besides,
some risk factors identified to predict bone fracture in
the study, such as peripheral vascular disease and neuro-
logic problems, are also at least partly related to AKI.
The results from the study additionally offer an insight
into the impact of bone disease [92].
Kidney-hepatic crosstalk
Though the clinical evidence of the association between
acute liver injury and AKI is well documented, the
mechanisms and pathways between kidney-hepatic
crosstalk remains to be investigated [95]. An experimen-
tal study showed that hepatic ischemic/reperfusion in-
jury (HIRI) abrupt increases multiple cytoprotective
proteins, such as neutrophil gelatinase-associated lipoca-
lin (NGAL), heme oxygenase-1 and hepcidin, inducing a
renal cortical “stress response” [96]. Though modest
azotemia occurs, the HIRI-induced azotemia appears to
a pre-renal state rather than an intrinsic renal damage.
Thus, despite clinical evidence of acute liver injury pre-
dispose to AKI, it seems plausible that AKI contributes
to subsequent liver damage more directly. Growing evi-
dence showed that AKI has significant effect on liver in-
flammatory response, as well as drug or other nutrientmetabolism, and even patient outcomes [19]. Experi-
mental studies showed that AKI results in increased
vascular permeability, neutrophil and T-lymphocyte in-
filtration in the liver [18]. Besides, AKI activates oxida-
tive stress, decreases antioxidants level and upregulate
the expression of injury-promoting molecules, leading to
apoptosis and tissue damage of hepatocytes [30, 97].
Among the related cytokines, IL-6 is a well-known one
induced in AKI and could activate Kuffer cell to further
produce other inflammatory cytokines including IL-10
[98]. As to the results of clinical studies, an analysis
from a randomized control study found that the occur-
rence of a subsequent AKI would increase mortality
rate from 28 % to 58 % among patients with acute liver
injury [99].
Kidney-malignancy
A nationwide population study using 1,000,000 represen-
tative database during 2000–2008 was conducted by Chao
et al. [100] who identified 623 individuals recovering from
RRT-requiring AKI (recovery-AKI group) and 623 pa-
tients developing ESRD during follow-up (non-recovery
AKI group), along with an age, sex, and diabetes status-
matched control group (non-AKI group). After a mean
follow-up period of 3.7 years, the standardized incidence
ratios of all cancers are higher in both recovery-AKI group
(1.21) and non-recovery AKI group (1.31) when using
general population as reference. And the incidences
of de novo malignancy were gradually increased from
“no-AKI group”, “recovery-AKI group”, to “non-recovery
AKI group” (2.6, 2.9, and 4.2 per 100 person-year, re-
spectively). Overall speaking digestive tract (4.9 %),
Genitourinary tract (3.0 %), and respiratory tract (1.7 %)
were the top three sites of de novo cancers occurrence.
Comparing with the “recovery-AKI group”, the “no-AKI
group” had lower risk (HR, 0.66) while the “non-recov-
ery AKI group” had higher risk (HR, 1.44) of developing
malignancy.
This study demonstrates patients with non-recovery
AKI developed more genitourinary cancers (5.1 %), while
recovery patients developed more respiratory tract can-
cers (2.2 %) in the long run. The relationship presumably
includes viral carcinogenesis, uremic immune suppres-
sion, and toxin exposure. The acute or chronic inflam-
mation and the ensuing regeneration processes might
carry the possibility of promoting the subsequent uncon-
trollable proliferation and neoplasm formation [50]. The
increase in protein binding uremic toxin during AKI also
could lead to epigenetic modification and potentially
increases chances of tumor-suppressor gene silencing
[66, 101]. This study shows patients requiring even tem-
porary RRT have higher long-term risk of developing
cancers, independent of subsequent progression to CKD
and ESRD.
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In the current review, the development of severe AKI
requiring RRT is found to have significant impact on
long-term morbidities of distant organs. These epi-
demiological findings in large-scaled population studies
echo and add much strength to the proposed underlying
mechanisms and involved pathways in organ crosstalk of
AKI. Besides, Pickering et al. [102] evaluated trial out-
comes using mathematic modeling of serum creatinine
(SCr) changes in AKI, and found that the “time of SCr
elevation” (duration of AKI) is associated with an effi-
cient outcome-predictive power. These could explain the
impact of recovery status on patient outcomes. From the
nationwide population studies comparing the effects
from AKI with different recovery status (recovery versus
non-recovery AKI) [68, 87, 100, 103], the “AKI dur-
ation”-dependent effect of long-term distant organ injury
from RRT-requiring AKI represent its real impact.
Similar results were also revealed among patients with
less severe form of AKI not requiring RRT support, no
matter the study focused on diabetic population [104] or
not [105]. The findings indicated that the AKI per se, be-
side RRT, speaks for itself. Recently, a retrospective mul-
ticenter study enrolling 447 critically-ill patients from
six intensive care units evaluated the impact of duration
(transient and persistent AKI) and severity of AKI (stage
3 AKI) on patient outcomes [106]. After adjustment with
all confounding factors, “persistent AKI” was found as
an independent factor associated with worse hospital
survival. However, when “stage 3 AKI” was put into the
final multivariate medel, “stage 3 AKI” replaced “persist-
ent AKI” as an independent factor with lower survival.
The findings are interesting and may be interpreted that
“severity of AKI” is more relevant than “duration of
AKI” in influencing patient prognosis.
An episode of AKI is proven to result in prolonged im-
pairment of renal blood flow and clearance even the SCr
has apparently returned to baseline [107]. Maladaptive
repair after AKI, which is characterized by persistent
parenchymal inflammation with increased numbers of
myofibroblasts and accumulation of extracellular matrix,
may lead to CKD. And the risk factors for the maladap-
tive repair response include the type and duration of
injury [108].
The exact causative association between AKI and the
long-term distant organ injury risks is still not clearly rec-
ognized [109]. Nonetheless, when the risk factors that had
engendered an AKI event may persist [110] and concomi-
tantly or subsequently lead to distant organ damage with-
out direct causal association between the past CKD.
Cytokine surge during AKI is at least partly resulted from
subsequent impaired filtration and clearance of uremic
toxins, and its impact is thought to attribute to the remote
damage between kidney and distant organs [18]. Althoughit is seemingly intuitive that the duration of AKI would be
positively associated with remote organ damage, the direct
evidence addressing this is lacking.
The findings from aforementioned studies raise the
possibility that AKI might trigger a cascade of perturba-
tions which are not completely resolved. And certain
non-traditional risk factors, such as impaired endothelial
progenitor cells, endothelial dysfunction, inflammatory
response, oxidative stress, hyper-homocysteinemia, and
thrombogenic factors during AKI, are involved in the he
pathogenic mechanisms [111, 112]. These risk factors
may play a role in accelerated atherosclerosis in the ar-
teries of both the kidney and remote organs, making
AKI a non-modifiable entity. Besides, the RRT hemofil-
trate from AKI patients inhibited in vitro neutrophil
chemotaxis, oxidative metabolism, and apoptosis, which
could favorably affect endothelial evolution [113]. Taken
together, AKI, in addition to the traditional cardiovascu-
lar equivalent, serves as a “kidney specific” risk factor as-
sociated with distant organ injury.
Since AKI is known as a contributing factor to late-
stage CKD, it is possible that early kidney changes involv-
ing endothelial phenotypic transition may have already
taken place during acute events, paving the way toward
progressive renal function deterioration. Recently, FGF-
23, a novel regulator of mineral metabolism which is
markedly elevated in AKI [114], is regarded as an index of
subclinical cardiovascular pathology and associated with
adverse cardiovascular outcome [115]. Likewise, the ex-
pression of NGAL, a marker of renal tubular injury, is also
related to increased cardiovascular and all-cause mortality
independent of traditional cardiovascular risk factors [116].
Besides the concept of organ crosstalk during AKI that
AKI itself could cause a number of systemic vascular
endothelial alterations which impact cardiovascular
health [109], some possible explanations for the remote
organ injury from recoverable AKI are summarized
below. First, AKI may serve as a surrogate of other end-
organ damages. A recoverable AKI may be a less severe
AKI event which itself does not cause damage but
merely reflects a sicker patient population who have less
renal reserve and more subsequent medical complica-
tions. Second, regardless renal recovery status, AKI pa-
tients had higher probability to be hospitalized for a
longer duration than those without AKI, thus may get
higher risks of medical complications [105].
Among the managements of AKI-related remote organ
consequences, early identifying and stratifying patient in
risk, as well as preventive measures to avoid the occur-
rence and evolution of AKI are the most important
strategy. Over the past decade, many novel biomarkers
with important biological function in the pathogenesis of
AKI were identified and validated. Generally speaking,
the biomarkers of AKI are categorized into three groups,
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α1- or β2-microglobulin), tubular enzymes (such as α-
glutathione-S-transferase (α-GST)), and unregulated
proteins (such as NGAL, L-type fatty acid-binding pro-
tein (L-FABP), kidney injury molecule-1 (KIM-1) and
IL-18) [117].
A rapidly elevated urine concentration of NGAL, L-
FABP, α-GST, KIM-1, and IL-18 is indicative of AKI,
achieving an early detection of AKI about 24 to 48 hours
before the rise of SCr level [118]. According to the var-
ied characteristic of individual biomarker along with the
concentration change in serum and urine sample, the
biomarkers are also valuable in making differential diag-
nosis of AKI among the critically ill patients [119]. Be-
sides, the elevated level of some biomarkers are of
important prognostic value. An early assessment of
prognosis may result in better outcomes [119].
Since cytokines and chemokines were thought to
play important roles in the organ crosstalk in AKI
[18, 19, 21, 30, 39], it is reasonable to consider “remov-
ing cytokines/chemokines” as a potential management
strategy to preventing remote organ damage following
AKI. Although hemofiltration could remove inflammatory
cytokines, it does not affect patient mortality rates regard-
less the amount of applied dosage among the patients with
septic shock in which inflammatory mediators contribute
to patients outcomes [120]. Actually, standard dialysis
membrane could only remove limited amount of cyto-
kines even with high volume hemofiltration [121]. A kind
of recently-developed dialysis membranes with moderately
larger pore size, called high cutoff membranes, is found to
have better effectiveness in removing cytokines than
standard membranes and associated with better immuno-
logic function and survival in experimental models of
sepsis [17, 122]. Besides, “coupled plasma filtration and
adsorption” is found to improve function of immunity and
circulating leukocytes in septic shock [123], while “poly-
mycin B hemoperfusion” is suggestive of beneficial effect
on arterial pressure, gas exchange, and mortality [124].
However, the evidence exactly focusing on the association
between RRT and remote organ consequence is lacking.
Further large-scaled, prospective study is warranted to
evaluated the association among RRT intervention, cyto-
kines/chemokines/oxidative stress, and remote organs in-
jury, in AKI patients undergoing optimized RRT in a way
that the multiple negative effects of the acute uremic state
are mitigated.
Conclusion
In conclusion, an increasing body of research demon-
strated the organ crosstalk during AKI has significant im-
pact on long-term distant organ-system comorbidities, the
impact persist despite subsequent renal function recovery.
Recognizing key biomarkers of inflammation as noveltherapeutic targets may improve the quality of diagnosis
and therapy since cytokines and chemokines play import-
ant roles in the distant organ injury during AKI. Besides,
optimizing RRT for remove certain cytokines, as well as
decreasing inflammatory and acute uremic status may
probably be a useful strategy to avoid distant organ injury.
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